Muscle Mass Via UltraSound in Cirrhosis (MMUSCLE)
Key facts
- Who runs it
- University Hospital, Antwerp
- Where
- Belgium1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 6 May 2024
- Expected to end
- 31 Mar 2028
- Type of study
- Observational, 3 groups
- Treatments tested
- ultrasound
- Record updated
- 1 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- diagnosis of cirrhosis and follow-up in the University Hospital of Antwerp
Who cannot take part
- a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours
- no complete remission of malignancy including hepatocellular carcinoma within the past 12 months
- known patient will against participation in the study or against the measures applied in the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational cohort study is to learn about loss of muscle mass and muscle strength (sarcopenia) in patients with cirrhosis. The main question[s] it aims to answer are:
Read full original descriptionShow less
* what is the prevalence and development of sarcopenia in cirrhosis? * what is the role of malnutrition? Participants will
* undergo a muscle ultrasound of the lower and upper limb muscles * handgrip strength will be measured * malnutrition screening and assessment * complete a questionnaire to assess quality of life
The 3 groups in the trial
- Child A
The impact of sarcopenia in patients with cirrhosis may also be influenced by sex, severity of hepatic dysfunction, and etiology of cirrhosis. For this reason we aim for an homogeneous population, with a balanced distribution over the Child Pugh classification with a homogeneous population of at least 50%. Child A patients still have a good hepatic function.
Treatment: ultrasound
- Child B
Child B patients have a moderately impaired hepatic function.
Treatment: ultrasound
- Child C
Patients with Child C have an advanced hepatic dysfunction, within this group we will also look at patients with acute on chronic liver failure.(ACLF)
Treatment: ultrasound
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prospective Observational Cohort Survey to Assess the Prevalence and Development of Sarcopenia and the Correlation of Muscle Mass and Outcome in Patients With Cirrhosis by Skeletal Muscle Ultrasound.
- Record updated
- 1 May 2026